Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Luciano J Costa, et al. on X:
“Yesterday I learned that teclistamab & talquetamab are approved in Mexico for triple-class exposed Multiple Myeloma regardless of lines of therapy Love this!
So much more practical and scientifically sound. Some day we’ll be able to ditch LOT, and it’ll be our LMIC colleagues leading the charge!”
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.
Authors: Luciano J Costa, et al.
